Trial Profile
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cytarabine; Methotrexate; Procarbazine; Vincristine
- Indications B-cell lymphoma; CNS cancer; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 23 May 2022 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Primary endpoint (Progression free survival (PFS) defined as the interval from randomization to progression or death, whichever occurs first) has been met, as per Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology